What is FidoCure?
FidoCure is at the forefront of veterinary personalized medicine, specializing in the genomic analysis of canine cancers to create bespoke treatment plans. By moving beyond conventional therapies, FidoCure leverages cutting-edge genomic testing to match specific genetic profiles of dogs with the most effective therapeutic strategies. The company is building the world's largest proprietary cancer data set for canines, aiming to enhance the understanding and efficacy of cancer treatments for pets. Their services are designed to support veterinarians and pet owners, offering advanced options and improved prognoses for dogs facing cancer diagnoses.
How much funding has FidoCure raised?
FidoCure has raised a total of $10M across 1 funding round:
Other Financing Round
$10M
Other Financing Round (2020): $10M with participation from Lerer Hippeau, Andreessen Horowitz, Y-Combinator, Tau Ventures, Polaris Partners, and Borealis Ventures
Key Investors in FidoCure
Lerer Hippeau
Lerer Hippeau is a venture capital firm focused on investing in innovative startups, particularly in the early stages such as Seed and Pre-Seed rounds. They aim to support founders with great ideas who are willing to tackle challenging problems, fostering long-term success through their expertise as former operators.
Andreessen Horowitz
Andreessen Horowitz, commonly known as a16z, is a prominent venture capital firm that invests in technology companies. They are known for their deep engagement with portfolio companies, offering operational support and strategic guidance across various sectors of the tech industry.
Y-Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses. It is one of the most prestigious startup accelerators globally.
What's next for FidoCure?
With its recent major strategic investment, FidoCure is poised to accelerate its research and development initiatives, further expanding its genomic database and refining its personalized treatment protocols. The company's enterprise-level funding context suggests a strategic focus on scaling operations, forging key partnerships within the veterinary and pharmaceutical sectors, and potentially broadening its service offerings. FidoCure's commitment to innovation in canine cancer care positions it for significant impact and leadership in the growing field of veterinary precision medicine.
See full FidoCure company page
